Avicenna Alliance: enhanced knowledge, improved decisions, better outcomes
FULL MENU

Avicenna Alliance Task Forces

To effectively address critical questions related to the adoption and deployment of in silico methods for specific topics, the Avicenna Alliance has established dedicated Task Forces, composed of experts from various fields, ensuring a multidisciplinary approach to solving complex issues.

These groups collaborate to achieve concrete progress for matters as diverse as In silico AI, Patient involvement, Horizon Europe Projects, Pharmaceutical strategy, In silico oncology, Notified Bodies and Standard Organizations, etc.

By leveraging diverse expertise and fostering strong industry-academia relationships – each Task Force is led by 2 co-chairs one from academia and one from industry - the Task Forces aim to pave the way for widespread implementation and acceptance of in silico practices, ultimately benefiting patients and advancing scientific progress.


APAC Task Force International Affairs Working Group APAC Task Force Mission: Nurture a community of collaboration among Regulators, Industry, and Academia in the APAC region to advance in silico methods, best practices, and policies for Regulatory Science and Innovation Artificial intelligence (AI) Task Force Research & Technology Working Group Artificial intelligence (AI) Task Force Mission: Engage in all AA activities related to AI Cancer & In Silico Oncology Task Force Research & Technology Working Group Cancer & In Silico Oncology Task Force Mission: Accelerate, optimize and personalize cancer treatment through the development, clinical validation and clinical translation of in silico methods Clinical Deployment Task Force In Silico Application Working Group Clinical Deployment Task Force Mission: Promote use of in silico medicine from product development to clinical practice EMA Collaboration Task Force Policy Development Working Group EMA Collaboration Task Force Mission: Closely collaborate with the European Medicine Agency (EMA) to inform them about the progress of in silico methods and learn about EMA requirements to accept digital evidence Global Harmonization Task Force International Affairs Working Group Global Harmonization Task Force Mission: Inform and educate regulatory agencies around the world to ensure harmonized adoption of in silico methods Good Simulation Practice (GSP) Task Force Policy Development Working Group Good Simulation Practice (GSP) Task Force Mission: Drafting a Good Simulation Practice document widely recognized and accepted similar to the Good Clinical Practice Horizon Europe Task Force Research & Technology Working Group Horizon Europe Task Force Mission: Monitor, influence & inform on Horizon Europe Funding Nonclinical Application Task Force In Silico Application Working Group Nonclinical Application Task Force Mission: Promote use of in silico solutions to conduct smarter (3R’s) nonclinical studies Notified Bodies (NB) Task Force Policy Development Working Group Notified Bodies (NB) Task Force Mission: Systematic engagement with NBs to advance in silico trials in Europe Pharma / CMC Task Force In Silico Application Working Group Pharma / CMC Task Force Mission: Accelerate the adoption of in silico technologies in pharmaceutical development, Chemistry, Manufacturing and Controls (CMC), and regulatory decision-making throughout the product lifecycle. Public & Patient Involvement (PPI) Task Force Policy Development Working Group Public & Patient Involvement (PPI) Task Force Mission: Empower the public & patients to understand the potential of in silico medicine, improve healthcare creating ‘user demand’, encourage greater funding and drive broader clinical and regulatory adoption for enhanced impact Tissue Characterization Task Force Research & Technology Working Group Tissue Characterization Task Force Mission: Create a data base of biological tissue properties with Certificate of Birth UK In Silico Regulatory Innovation Task Force International Affairs Working Group UK In Silico Regulatory Innovation Task Force Mission: Nurture a cross-sector UK in silico trials community for regulatory science & innovation to produce evidence and harmonize standards in the UK accelerating in silico adoption in regulations

NEWS

News ADVANCING THE VIRTUAL HUMAN TWIN ECOSYSTEM - Avicenna Alliance at VHT Net Initiative Meeting

ADVANCING THE VIRTUAL HUMAN TWIN ECOSYSTEM - Avicenna Alliance at VHT Net Initiative Meeting

On 20 October, Avicenna Alliance was represented by many members and partners, including our President and Secretary General, Thierry Marchal, at the annual VHT Net initiative meeting, organised by the VPH - The Society for In Silico Medicine at the European Commission.

News SILICA General Assembly - Strengthening collaboration on AI, synthetic data and in silico methods in healthcare

SILICA General Assembly - Strengthening collaboration on AI, synthetic data and in silico methods in healthcare

The Avicenna Alliance is pleased to support initiatives that bring stakeholders together to advance the use of artificial intelligence, synthetic data, and computational modelling and simulation in healthcare.

News Avicenna Days (AAD) 2027

Avicenna Days (AAD) 2027

Three days. One journey. From research to real-world impact.

Sign up for our monthly newsletter!

Sign up for our monthly newsletter!

Fill in the fields you find below

Avicenna Alliance is an initiative of:

Avicenna VPH

© 2018-2026 Avicenna Alliance | powered by We Berry